Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

J Robert West MD Inc

Neither a doctor nor a teaching hospital

Research payments

$1,385,672

149 payments

Through program year 2025, J Robert West MD Inc is reported as receiving $1,385,672 in research payments, across 149 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $405,741 45
2024 Research $537,785 30
2023 Research $52,197 6
2022 Research $116,721 13
2021 Research $68,756 9
2020 Research $85,243 25
2019 Research $119,229 21

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $536,748 50 payments
  2. AbbVie, Inc. $327,570 29 payments
  3. Allergan Inc. $246,567 41 payments
  4. Eli Lilly and Company $209,659 6 payments
  5. Merz North America, Inc. $46,493 18 payments
  6. Pfizer Inc. $18,635 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment $270,658 24 payments
  2. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $214,392 19 payments
  3. A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) $187,394 13 payments
  4. A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata $114,623 2 payments
  5. A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence $104,953 13 payments
  6. P2b BTX Platysma Study $103,922 13 payments
  7. Voluma Temple US $81,947 11 payments
  8. A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $50,903 2 payments
  9. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $46,698 6 payments
  10. A Phase 3 Double-Blind Randomized Placebo-Controlled Trial to Evaluate the Efficacy Safety and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata $38,659 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record